Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer.

ABSTRACT: Recurrent, metastatic prostate cancer continues to be a leading cause of cancer-death in men. The androgen receptor (AR) is a modular, ligand-inducible transcription factor that regulates the expression of genes that can drive the progression of this disease, and as a consequence, this receptor is a key therapeutic target for controlling prostate cancer. The current drugs designed to directly inhibit the AR are called anti-androgens, and all act by competing with androgens for binding to the androgen/ligand binding site. Unfortunately, with the inevitable progression of the cancer to castration resistance, many of these drugs become ineffective. However, there are numerous other regulatory sites on this protein that have not been exploited therapeutically. The regulation of AR activity inv

SUBMITTER: Lallous N 

PROVIDER: S-EPMC3709796 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature